- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- December 2024
- 175 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- December 2024
- 175 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- August 2024
- 175 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- July 2024
- 175 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- July 2024
- 175 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- July 2024
- 175 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- July 2024
- 175 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- July 2024
- 175 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- March 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- March 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- March 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- March 2025
- 250 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- March 2025
- 175 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- March 2025
- 250 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP

The Viral Vector market is a subset of the biotechnology industry that focuses on the development and production of viral vectors for gene therapy. Viral vectors are modified viruses that are used to deliver genetic material into cells, allowing for the expression of a desired gene. This technology has been used to treat a variety of diseases, including cancer, genetic disorders, and infectious diseases.
Viral vectors are produced through a variety of methods, including recombinant DNA technology, synthetic biology, and cell-based systems. The production of viral vectors requires specialized equipment and expertise, making it a highly specialized field.
The Viral Vector market is highly competitive, with a number of companies offering products and services. Some of the major players in the market include Novartis, Merck, Pfizer, AstraZeneca, and Sanofi. Additionally, there are a number of smaller companies that specialize in the production of viral vectors, such as Viralgen, Oxford BioMedica, and Vigene Biosciences. Show Less Read more